» Articles » PMID: 34100559

Vitamin D Supplementation for Children with Cancer: A Systematic Review and Consensus Recommendations

Overview
Journal Cancer Med
Specialty Oncology
Date 2021 Jun 8
PMID 34100559
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Prevalent vitamin D deficiency (VDD) and low bone mineral density (BMD) have led to vitamin D supplementation for children with cancer, regardless vitamin D status. However, it remains unsettled whether this enhances bone strength. We sought to address this issue by carrying out a systematic review of the literature.

Methods: We conducted a literature search using PubMed, Embase, and Cochrane databases. Studies including children up to 5 years after cancer therapy were assessed for the association between 25-hydroxyvitamin D (25OHD) levels and BMD Z-scores or fractures, and the effect of vitamin D supplementation on BMD or fractures. Evidence quality was assessed using the GRADE methodology.

Results: Nineteen studies (16 observational and 3 interventional, mainly involving children with hematologic malignancies) were included. One study which analyzed 25OHD as a threshold variable (≤10 ng/ml) found a significant association between 25OHD levels and BMD Z-scores, while 25OHD as a continuous variable was not significantly associated with BMD Z-scores in 14 observational studies. We found neither a significant association between lower 25OHD levels and fractures (2 studies), nor between vitamin D (and calcium) supplementation and BMD or fracture frequency (3 studies) (very low quality evidence).

Conclusion: There is a lack of evidence for an effect of vitamin D (and calcium) supplementation on BMD or fractures in children with cancer. Further research is needed; until then, we recommend dietary vitamin D/calcium intake in keeping with standard national guidelines, and periodic 25OHD monitoring to detect levels <20 ng/ml. Vitamin D/calcium supplementation is recommended in children with low levels, to maintain levels ≥20 ng/ml year-long.

Citing Articles

Are Pediatric Cancer Patients a Risk Group for Vitamin D Deficiency? A Systematic Review.

Alexandru A, Ivan C, Tanasescu S, Oprisoni L, Dragomir T, Varga N Cancers (Basel). 2025; 16(24.

PMID: 39766100 PMC: 11674856. DOI: 10.3390/cancers16244201.


Bone health in childhood cancer survivors, is there really a problem? Pitfalls of assessment, calculating risk, and suggested surveillance and management for osteonecrosis and low and very low bone mineral density.

de Winter D, Neggers S, van den Heuvel-Eibrink M, van Atteveld J Endocr Connect. 2024; 13(12).

PMID: 39437150 PMC: 11623254. DOI: 10.1530/EC-24-0487.


Vitamin D Deficiency in Pediatric Oncology Patients: A Single-Center Experience in Saudi Arabia.

Monagel D, Albaity A, Asiri F, Alghamdi L, Alsufyani R, Alqarni R Cureus. 2024; 16(2):e54807.

PMID: 38529460 PMC: 10961921. DOI: 10.7759/cureus.54807.


Demographic and disease-related factors impact bone turnover and vitamin D in children with hemato-oncological diseases.

Jackmann N, Gustafsson J, Utriainen P, Magnusson P, Harila A, Atanasova D JBMR Plus. 2024; 8(4):ziae017.

PMID: 38523666 PMC: 10961176. DOI: 10.1093/jbmrpl/ziae017.


An evidence gap map of interventions for noncommunicable diseases and risk factors among children and adolescents.

Salam R, Khan M, Meerza S, Das J, Lewis-Watts L, Bhutta Z Nat Med. 2024; 30(1):290-301.

PMID: 38195753 DOI: 10.1038/s41591-023-02737-2.


References
1.
Choeyprasert W, Yansomdet T, Natesirinilkul R, Wejaphikul K, Charoenkwan P . Adverse effects of imatinib in children with chronic myelogenous leukemia. Pediatr Int. 2016; 59(3):286-292. DOI: 10.1111/ped.13136. View

2.
LeMay V, Caru M, Samoilenko M, Drouin S, Alos N, Lefebvre G . Prevention of Long-term Adverse Health Outcomes With Cardiorespiratory Fitness and Physical Activity in Childhood Acute Lymphoblastic Leukemia Survivors. J Pediatr Hematol Oncol. 2019; 41(7):e450-e458. DOI: 10.1097/MPH.0000000000001426. View

3.
Lips P, CHAPUY M, Dawson-Hughes B, Pols H, Holick M . An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int. 1999; 9(5):394-7. DOI: 10.1007/s001980050162. View

4.
Mostoufi-Moab S, Halton J . Bone morbidity in childhood leukemia: epidemiology, mechanisms, diagnosis, and treatment. Curr Osteoporos Rep. 2014; 12(3):300-12. PMC: 4131149. DOI: 10.1007/s11914-014-0222-3. View

5.
Kelly K, Thornton J, Hughes D, Osunkwo I, Weiner M, Wang J . Total body bone measurements: a cross-sectional study in children with acute lymphoblastic leukemia during and following completion of therapy. Pediatr Blood Cancer. 2008; 52(1):33-8. DOI: 10.1002/pbc.21760. View